HM2/MMAE antibody-drug conjugate ALT-P7

{
  "id": "MLC-T-ONC-014154",
  "term": "HM2/MMAE antibody-drug conjugate ALT-P7",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of the trastuzumab biobetter HM2 conjugated, in a site-specific manner, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of ALT-P7, the antibody moiety targets and binds to human epidermal growth factor receptor 2 (HER2) on tumor cells. Upon antibody/antigen binding and internalization, the MMAE moiety is released, binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. HER2 is a receptor tyrosine kinase (RTK) that is overexpressed by many cancer cell types.",
  "synonyms": [
    "HM2/MMAE ADC ALT-P7",
    "ADC ALT-P7",
    "HM2-MMAE"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/hm2-mmae-antibody-drug-conjugate-alt-p7/"
}